Condition: End-Stage Renal Disease · Sponsor: LifeNet Health
Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,
This description comes directly from the study's public registry record.
Kimberly Dorsch · 757-609-4378 · kimberly_dorsch@lifenethealth.org
Monique Alston-Epps · 757-713-4657 · monique_alstonepps@lifenethealth.org
Always discuss trial participation with your own doctor first.
| Infirmary Heath | Mobile, Alabama, United States | Recruiting |
| Olive View - UCLA Medical Center | Sylmar, California, United States | Recruiting |
| Harbor-UCLA Medical Center | Torrance, California, United States | Recruiting |
| Sentara Norfolk General Hospital | Norfolk, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05880537